|
February 3, 2010
|
| 08:48 EDT |  | WCRX |
| theflyonthewall.com: | Warner Chilcott pullback presents buying opportunity, says Leerink | | Leerink believes Warner Chilcott's earnings power remains underappreciated and finds shares attractively valued at current levels. The firm sees a buying opportunity following the recent pullback in shares and maintains an Outperform rating. :theflyonthewall.com |
|
|
February 2, 2010
|
| 16:36 EDT |  | WCRX |
|
| 09:01 EDT |  | WCRX |
|
|
February 1, 2010
|
| 09:30 EDT | | WCRX |
|
| 09:00 EDT |  | WCRX |
| theflyonthewall.com: | On The Fly: Analysts Downgrade Summary | | MOST NOTEWORTHY: Lubrizol (LZ), Cytec Industries (CYT), L-1 Identity (ID) and Cogent (COGT) were today's noteworthy downgrades: Citigroup downgraded Lubrizol to Sell from Hold on margin concerns after the company's competitor NewMarket and customer Valvoline reported a decline in Q4 margins. Citi lowered its target price on shares to $67 from $78. Deutsche Bank downgraded Cytec Industries to Hold from Buy on 2010 concerns, which include rising raw materials and lower aerospace volumes. The firm lowered its target on shares to $38 from $42. JP Morgan downgraded L-1 Identity and Cogent to Underweight from Neutral to reflect a negative outlook for the biometric sector in 2010. The firm has an $8 target on L-1 and an $11.50 price target on Cogent shares...OTHER DOWNGRADES: Arch Coal (ACI) was cut to Market Perform from Outperform at BMO capital. Warner Chilcott (WCRX) was downgraded to Equal Weight from Overweight at Morgan Stanley. Provident Financial (PFS) was downgraded to Neutral from Buy at Janney Montgomery. :theflyonthewall.com |
|
| 07:34 EDT |  | WCRX |
|
|
January 29, 2010
|
| 09:41 EDT |  | WCRX |
|
| 08:01 EDT |  | WCRX |
| theflyonthewall.com: | Warner Chilcott to host conference call | | Conference call to discuss 2010 financial guidance will be held on January 29 at 8:30 am. Webcast Link :theflyonthewall.com |
|
| 07:32 EDT |  | WCRX |
| theflyonthewall.com: | Warner Chilcott sees FY10 EPS $3.30-$3.40 vs. consensus of $3.14 | | Sees FY10 adjusted revenues $2.9B-$2.95B vs. consensus of $3.01B. :theflyonthewall.com |
|
|
January 28, 2010
|
| 06:16 EDT | | WCRX |
|
|
January 27, 2010
|
| 16:35 EDT |  | WCRX |
|
|
January 26, 2010
|
| 07:34 EDT | | WCRX |
| theflyonthewall.com: | Warner Chilcott's WC-3016 is a low dose oral contraceptive | | Warner Chilcott's New Drug Application (NDA) for WC-3016 has an FDA PDUFA Date of January 26, 2010. :theflyonthewall.com |
|
Subscribe for More Information